Kit, device and method for diagnosing lung cancer

Abstract

The present invention discloses the application of exosomal miR-106b-3p, miR-450b-5p, etc. in the diagnosis of lung cancer. The kit includes primers and probes for detecting exosomal miRNA markers, and the exosomal miRNA markers include one or more of let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706, miR-885-5p. The present invention provides a non-invasive method for diagnosing lung cancer based on exosomes, which has high sensitivity and high specificity in lung cancer, provides important value for the early diagnosis and recurrence monitoring of lung cancer, and is of great help for the prevention and treatment of lung cancer in China.

Description

[0001] This application is a divisional application. The relevant divisional application number is 202111059955.0, the application date is May 11, 2020, and the invention title is "Kit, device and method for lung cancer diagnosis". Technical Field

[0002] The present invention relates to the field of medical diagnosis, and particularly relates to a diagnostic kit, device and method for early lung cancer. Background Art

[0003] With the application of low-dose spiral CT, more and more imaging findings show pulmonary nodules (single lesions within 3 cm in the pulmonary interstitium without associated atelectasis or lymphadenopathy) are found. However, not all pulmonary nodules are malignant. The differential diagnosis of benign and malignant pulmonary nodules has always been a difficult point in the clinical diagnosis and treatment of thoracic surgery. Currently, non-invasive detection methods such as plasma circulating tumor cells and circulating tumor-free DNA are also used, but their detection sensitivity in the diagnosis of early lung cancer is not high; therefore, there is an urgent need to develop a method for non-invasive early detection of lung cancer with high sensitivity. Summary of the Invention

[0004] The present invention provides a reagent, device and method for non-invasive early lung cancer diagnosis based on exosomes.

[0005] On the one hand, the present invention provides a kit for lung cancer diagnosis, including primers and probes for detecting exosomal miRNA markers, and the exosomal miRNA markers include one or more of let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706, miR-885-5p.

[0006] Preferably, the exosomal miRNA markers are one or a combination of miR-3615, miR-502-3p, miR-450b-5p, miR-4746-5p, miR-10a-5p, miR-106b-3p, miR-125a-5p, miR-885-5p.

[0007] Preferably, the exosomal miRNA markers are a combination of miR-106-3p, miR-125a-5p, and miR-3615.

[0008] Preferably, the exosomal miRNA markers are a combination of miR-106b-3p, miR-3615, and miR-450b-5p.

[0009] Preferably, the exosomal miRNA markers are a combination of miR-106b-3p, miR-125a-5p, miR-3615, miR-450b-5p, and miR-885-5p.

[0010] Preferably, the exosomal miRNA markers are a combination of miR-106b-3p, miR-10a-3p, miR-125a-5p, miR-3615, and miR-450b-5p.

[0011] Preferably, the exosomal source includes one or more of blood, saliva, and sputum.

[0012] Preferably, the primers and probes include:

[0013] Reverse transcription primer, PCR primer, and probe for detecting let-7a-3p: The reverse transcription primer for let-7a-3p has the nucleotide sequence shown in SEQ ID NO: 1, the PCR upstream primer has the nucleotide sequence shown in SEQ ID NO: 2, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 3;

[0014] Reverse transcription primer, PCR primer, and probe for detecting let-7f-2: The reverse transcription primer for let-7f-2 has the nucleotide sequence shown in SEQ ID NO: 4, the PCR upstream primer has the nucleotide sequence shown in SEQ ID NO: 5, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 6;

[0015] Reverse transcription primer, PCR primer, and probe for detecting miR-106b-3p: The reverse transcription primer for miR-106b-3p has the nucleotide sequence shown in SEQ ID NO: 7, the PCR upstream primer has the nucleotide sequence shown in SEQ ID NO: 8, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 9;

[0016] Reverse transcription primers, PCR primers and probes for detecting miR-10a-3p: The reverse transcription primer for miR-10a-3p has the nucleotide sequence shown in SEQ ID NO: 10, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 11, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 12;

[0017] Reverse transcription primers, PCR primers and probes for detecting miR-10a-5p: The reverse transcription primer for miR-10a-5p has the nucleotide sequence shown in SEQ ID NO: 13, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 14, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 15;

[0018] Reverse transcription primers, PCR primers and probes for detecting miR-125a-5p: The reverse transcription primer for miR-125a-5p has the nucleotide sequence shown in SEQ ID NO: 16, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 17, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 18;

[0019] Reverse transcription primers, PCR primers and probes for detecting miR-1294: The reverse transcription primer for miR-1294 has the nucleotide sequence shown in SEQ ID NO: 19, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 20, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 21;

[0020] Reverse transcription primers, PCR primers and probes for detecting miR-19a-3p: The reverse transcription primer for miR-19a-3p has the nucleotide sequence shown in SEQ ID NO: 22, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 23, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 24;

[0021] Reverse transcription primers, PCR primers and probes for detecting miR-22-3p: The reverse transcription primer for miR-22-3p has the nucleotide sequence shown in SEQ ID NO: 25, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 26, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 27;

[0022] Reverse transcription primers, PCR primers and probes for detecting miR-29a-3p: The reverse transcription primer for miR-29a-3p has the nucleotide sequence shown in SEQ ID NO: 28, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 29, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 30;

[0023] Reverse transcription primers, PCR primers and probes for detecting miR-30e-5p: The reverse transcription primer of miR-30e-5p has the nucleotide sequence shown in SEQ ID NO: 31, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 32, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 33;

[0024] Reverse transcription primers, PCR primers and probes for detecting miR-3158-3p: The reverse transcription primer of miR-3158-3p has the nucleotide sequence shown in SEQ ID NO: 34, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 35, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 36;

[0025] Reverse transcription primers, PCR primers and probes for detecting miR-330-5p: The reverse transcription primer of miR-330-5p has the nucleotide sequence shown in SEQ ID NO: 37, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 38, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 39;

[0026] Reverse transcription primers, PCR primers and probes for detecting miR-3605-3p: The reverse transcription primer of miR-3605-3p has the nucleotide sequence shown in SEQ ID NO: 40, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 41, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 42;

[0027] Reverse transcription primers, PCR primers and probes for detecting miR-3615: The reverse transcription primer of miR-3615 has the nucleotide sequence shown in SEQ ID NO: 43, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 44, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 45;

[0028] Reverse transcription primers, PCR primers and probes for detecting miR-378h: The reverse transcription primer of miR-378h has the nucleotide sequence shown in SEQ ID NO: 46, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 47, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 48;

[0029] Reverse transcription primers, PCR primers and probes for detecting miR-425-3p: The reverse transcription primer for miR-425-3p has the nucleotide sequence shown in SEQ ID NO: 49, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 50, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 51;

[0030] Reverse transcription primers, PCR primers and probes for detecting miR-450b-5p: The reverse transcription primer for miR-450b-5p has the nucleotide sequence shown in SEQ ID NO: 52, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 53, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 54;

[0031] Reverse transcription primers, PCR primers and probes for detecting miR-4746-5p: The reverse transcription primer for miR-4746-5p has the nucleotide sequence shown in SEQ ID NO: 55, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 56, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 57;

[0032] Reverse transcription primers, PCR primers and probes for detecting miR-483-3p: The reverse transcription primer for miR-483-3p has the nucleotide sequence shown in SEQ ID NO: 58, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 59, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 60;

[0033] Reverse transcription primers, PCR primers and probes for detecting miR-502-3p: The reverse transcription primer for miR-502-3p has the nucleotide sequence shown in SEQ ID NO: 61, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 62, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 63;

[0034] Reverse transcription primers, PCR primers and probes for detecting miR-550a-5p: The reverse transcription primer for miR-550a-5p has the nucleotide sequence shown in SEQ ID NO: 64, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 65, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 66;

[0035] Reverse transcription primers, PCR primers and probes for detecting miR-651-5p: The reverse transcription primer of miR-651-5p has the nucleotide sequence shown in SEQ ID NO: 67, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 68, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 69;

[0036] Reverse transcription primers, PCR primers and probes for detecting miR-7706: The reverse transcription primer of miR-7706 has the nucleotide sequence shown in SEQ ID NO: 70, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 71, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 72;

[0037] Reverse transcription primers, PCR primers and probes for detecting miR-885-5p: The reverse transcription primer of miR-885-5p has the nucleotide sequence shown in SEQ ID NO: 73, the upstream PCR primer has the nucleotide sequence shown in SEQ ID NO: 74, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 75.

[0038] On the other hand, the present invention provides a device for lung cancer diagnosis, comprising reagents for detecting exosomal miRNA markers, wherein the exosomal miRNA markers include one or more of let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706, miR-885-5p.

[0039] On the other hand, the present invention provides a method for diagnosing lung cancer, including detecting the specificity of exosomal miRNA markers, and the exosomal miRNA markers include one or more of let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706, miR-885-5p.

[0040] The present invention provides a non-invasive method for diagnosing lung cancer based on exosomes, which has high sensitivity and high specificity in lung cancer, provides important value for the early diagnosis and recurrence monitoring of lung cancer, and is of great help to the prevention and treatment of lung cancer in China. Further, five of the miRNA markers (the combined AUC can reach up to 0.951, with a negative predictive value of 90.32%, a sensitivity of 90.00%, and a specificity of 93.33%) have extremely excellent diagnostic performance. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 are the results of electron microscopy identification of exosomes.

[0042] Figure 2 is the ROC curve of miR-3615 for single detection of lung cancer.

[0043] Figure 3 is the ROC curve of miR-502-3p for single detection of lung cancer.

[0044] Figure 4 is the ROC curve of miR-450b-5p for single detection of lung cancer.

[0045] Figure 5 is the ROC curve of miR-4746-5p for single detection of lung cancer.

[0046] Figure 6 is the ROC curve of miR-10a-5p for single detection of lung cancer.

[0047] Figure 7 is the ROC curve of the combination of miR-106-3p + miR-125a-5p + miR-3615 for detection of lung cancer.

[0048] Figure 8 The ROC curve of the combination of miR-106b-3p + miR-3615 + miR-450b-5p for detecting lung cancer.

[0049] Figure 9 The ROC curve of the combination of miR-106b-3p + miR-125a-5p + miR-3615 + miR-450b-5p + miR-885-5 for detecting lung cancer.

[0050] Figure 10 The ROC curve of the combination of miR-106b-3p + miR-10a-3p + miR-125a-5p + miR-3615 + miR-450b-5p for detecting lung cancer.

[0051] Figure 11 The ROC curve of the combination of miR-106b-3P + miR-10a-5p + miR-125a-5p + miR-3615 + miR-450b-5p for detecting lung cancer (using U6 as a reference). Detailed implementation manner

[0052] Extracellular Vesicles (EVs; hereinafter, vesicles all represent extracellular vesicles) refer to vesicular bodies with a double-membrane structure that are shed from the cell membrane or secreted by cells, with diameters ranging from 30 to 1000 nm. Extracellular vesicles mainly consist of MicroVesicles (MVs) and exosomes. Microvesicles are small vesicles shed from the cell membrane after cell activation or injury. Due to the unique biological characteristics of extracellular vesicles, they have important significance in disease diagnosis, especially exosomes among them.

[0053] Exosomes are membranous small vesicles with a diameter between 30 and 150 nm that are secreted into the extracellular environment after the fusion of intracellular multivesicular bodies with the cell membrane. They are important mediators of intercellular information transmission and play important roles in antigen presentation, apoptosis, inflammatory response, tumorigenesis, development, and metastasis. They are widely distributed in body fluids, including blood, saliva, urine, milk, and pleural and peritoneal effusions, etc.; contain various inclusions such as DNA, RNA, and proteins, and can be used as non-invasive diagnostic markers for various diseases such as tumors. And miRNA is the most abundant nucleic acid component in exosomes, so exosomal miRNA has the potential for early diagnosis of lung cancer.

[0054] The kit, device, and method provided by the present invention use one or more of the miRNAs that show significant differential expression in the exosomes of patients with early lung cancer found through experimental research as markers for diagnosing early lung cancer.

[0055] The significantly differentially expressed miRNAs include: let-7a-3p, let-7f-2, miR-106b-3p, miR-10a-3p, miR-10a-5p, miR-125a-5p, miR-1294, miR-19a-3p, miR-22-3p, miR-29a-3p, miR-30e-5p, miR-3158-3p, miR-330-5p, miR-3605-3p, miR-3615, miR-378h, miR-425-3p, miR-450b-5p, miR-4746-5p, miR-483-3p, miR-502-3p, miR-550a-5p, miR-651-5p, miR-7706, miR-885-5p.

[0056] In some preferred embodiments, the significantly differentially expressed miRNA molecular markers are used in combination, and a preferred combination is: one or more combinations of miR-3615, miR-502-3p, miR-450b-5p, miR-4746-5p, miR-10a-5p, miR-106b-3p, miR-125a-5p, miR-885-5p. The above combination can provide a better basis for the early diagnosis of lung cancer and predict disease risk.

[0057] In addition, the kit for diagnosing lung cancer of the present invention includes primers and probes for detecting the above-mentioned exosomal miRNA markers. The primers and probes for detecting exosomal miRNA markers include:

[0058] Reverse transcription primer, PCR primer and probe for detecting let-7a-3p: The reverse transcription primer of let-7a-3p has the nucleotide sequence shown in SEQ ID NO: 1, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 2, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 3;

[0059] Reverse transcription primer, PCR primer and probe for detecting let-7f-2: The reverse transcription primer of let-7f-2 has the nucleotide sequence shown in SEQ ID NO: 4, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 5, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 6;

[0060] Reverse transcription primers, PCR primers and probes for detecting miR-106b-3p: The reverse transcription primer of miR-106b-3p has the nucleotide sequence shown in SEQ ID NO: 7, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 8, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 9;

[0061] Reverse transcription primers, PCR primers and probes for detecting miR-10a-3p: The reverse transcription primer of miR-10a-3p has the nucleotide sequence shown in SEQ ID NO: 10, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 11, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 12;

[0062] Reverse transcription primers, PCR primers and probes for detecting miR-10a-5p: The reverse transcription primer of miR-10a-5p has the nucleotide sequence shown in SEQ ID NO: 13, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 14, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 15;

[0063] Reverse transcription primers, PCR primers and probes for detecting miR-125a-5p: The reverse transcription primer of miR-125a-5p has the nucleotide sequence shown in SEQ ID NO: 16, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 17, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 18;

[0064] Reverse transcription primers, PCR primers and probes for detecting miR-1294: The reverse transcription primer of miR-1294 has the nucleotide sequence shown in SEQ ID NO: 19, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 20, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 21;

[0065] Reverse transcription primers, PCR primers and probes for detecting miR-19a-3p: The reverse transcription primer of miR-19a-3p has the nucleotide sequence shown in SEQ ID NO: 22, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 23, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 24;

[0066] Reverse transcription primers, PCR primers and probes for detecting miR-22-3p: The reverse transcription primer of miR-22-3p has the nucleotide sequence shown in SEQ ID NO: 25, the upstream PCR primer specifically has the nucleotide sequence shown in SEQ ID NO: 26, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 27;

[0067] Reverse transcription primers, PCR primers and probes for detecting miR-29a-3p: The reverse transcription primer of miR-29a-3p has the nucleotide sequence shown in SEQ ID NO: 28, the upstream PCR primer specifically has the nucleotide sequence shown in SEQ ID NO: 29, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 30;

[0068] Reverse transcription primers, PCR primers and probes for detecting miR-30e-5p: The reverse transcription primer of miR-30e-5p has the nucleotide sequence shown in SEQ ID NO: 31, the upstream PCR primer specifically has the nucleotide sequence shown in SEQ ID NO: 32, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 33;

[0069] Reverse transcription primers, PCR primers and probes for detecting miR-3158-3p: The reverse transcription primer of miR-3158-3p has the nucleotide sequence shown in SEQ ID NO: 34, the upstream PCR primer specifically has the nucleotide sequence shown in SEQ ID NO: 35, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 36;

[0070] Reverse transcription primers, PCR primers and probes for detecting miR-330-5p: The reverse transcription primer of miR-330-5p has the nucleotide sequence shown in SEQ ID NO: 37, the upstream PCR primer specifically has the nucleotide sequence shown in SEQ ID NO: 38, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 39;

[0071] Reverse transcription primers, PCR primers and probes for detecting miR-3605-3p: The reverse transcription primer of miR-3605-3p has the nucleotide sequence shown in SEQ ID NO: 40, the upstream PCR primer specifically has the nucleotide sequence shown in SEQ ID NO: 41, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 42;

[0072] Reverse transcription primers, PCR primers and probes for detecting miR-3615: The reverse transcription primer of miR-3615 has the nucleotide sequence shown in SEQ ID NO: 43, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 44, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 45;

[0073] Reverse transcription primers, PCR primers and probes for detecting miR-378h: The reverse transcription primer of miR-378h has the nucleotide sequence shown in SEQ ID NO: 46, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 47, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 48;

[0074] Reverse transcription primers, PCR primers and probes for detecting miR-425-3p: The reverse transcription primer of miR-425-3p has the nucleotide sequence shown in SEQ ID NO: 49, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 50, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 51;

[0075] Reverse transcription primers, PCR primers and probes for detecting miR-450b-5p: The reverse transcription primer of miR-450b-5p has the nucleotide sequence shown in SEQ ID NO: 52, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 53, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 54;

[0076] Reverse transcription primers, PCR primers and probes for detecting miR-4746-5p: The reverse transcription primer of miR-4746-5p has the nucleotide sequence shown in SEQ ID NO: 55, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 56, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 57;

[0077] Reverse transcription primers, PCR primers and probes for detecting miR-483-3p: The reverse transcription primer of miR-483-3p has the nucleotide sequence shown in SEQ ID NO: 58, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 59, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 60;

[0078] Reverse transcription primers, PCR primers and probes for detecting miR-502-3p: The reverse transcription primer for miR-502-3p has the nucleotide sequence shown in SEQ ID NO: 61, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 62, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 63;

[0079] Reverse transcription primers, PCR primers and probes for detecting miR-550a-5p: The reverse transcription primer for miR-550a-5p has the nucleotide sequence shown in SEQ ID NO: 64, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 65, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 66;

[0080] Reverse transcription primers, PCR primers and probes for detecting miR-651-5p: The reverse transcription primer for miR-651-5p has the nucleotide sequence shown in SEQ ID NO: 67, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 68, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 69;

[0081] Reverse transcription primers, PCR primers and probes for detecting miR-7706: The reverse transcription primer for miR-7706 has the nucleotide sequence shown in SEQ ID NO: 70, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 71, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 72;

[0082] Reverse transcription primers, PCR primers and probes for detecting miR-885-5p: The reverse transcription primer for miR-885-5p has the nucleotide sequence shown in SEQ ID NO: 73, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 74, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 75;

[0083] Reverse transcription primers, PCR primers and probes for detecting the internal reference U6: The reverse transcription primer for U6 has the nucleotide sequence shown in SEQ ID NO: 78, the PCR upstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 76, the downstream primer specifically has the nucleotide sequence shown in SEQ ID NO: 78, and the probe has the nucleotide sequence shown in SEQ ID NO: 79. The nucleotide sequences of the primers and probes are shown in Table 1.

[0084] Table 1

[0085]

[0086]

[0087]

[0088] Furthermore, the sources of exosomes include one or more of blood, saliva and sputum.

[0089] The kits, devices and methods of the present invention are applicable to individuals who are at high risk of lung cancer, normal individuals and patients after lung cancer surgery.

[0090] The technical solutions of the present invention will be described completely and clearly below in conjunction with the embodiments. The described embodiments are part of the embodiments of the present invention, rather than all of the examples. Based on the embodiments of the present invention, other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the scope of protection of the present invention.

[0091] The experimental methods in the following embodiments are all conventional methods unless otherwise specified. The materials, reagents, etc. used in the following embodiments can all be obtained from commercial channels unless otherwise specified.

[0092] In order to screen for exosome markers related to the diagnosis of lung cancer, 50 early-stage lung cancer patients and 72 controls were recruited. At least 10 ml of blood was collected and plasma was separated. The exosomes in the plasma were separated by the classical ultracentrifugation method and RNA was extracted. The obtained RNA was used for RNA library construction and sequencing respectively. The obtained data were subjected to bioinformatics analysis to compare the differentially expressed RNAs in early-stage lung cancer patients and controls. These mRNA-level markers from exosomes can be used for the early diagnosis of lung cancer.

[0093] Furthermore, the application analysis of the RNA markers was carried out as follows: (1) Collect body fluid samples (including blood, sputum and saliva) of the individual to be tested; (2) Separate exosomes in the body fluid; (3) Extract exosome RNA with spkin external reference cel-miR-39; (4) Detect the expression level of the target RNA by a two-step method; (5) Normalize the expression level of the detected target RNA using the external reference gene; (6) Substitute the normalized gene expression level into the determination model to obtain the output value; (7) Determine whether the individual to be tested has lung cancer according to the output value of the model and the determination threshold.

[0094] The kit includes PCR primers, probes, standards for detecting exosome RmiNA markers and a two-step detection system for reverse addition PCR.

[0095] Quantification of target RNA was performed by selecting either exogenous reference Cel-miR-39 or endogenous reference U6. When selecting a reference, the expression level of the biomarker was calculated using the quantitative formula 2ΔΔCt based on the detected Ct value for the quantification of target RNA. After obtaining the expression level of the target RNA, the ROC curve and AUC were used to evaluate the accuracy of detecting lung cancer using a single RNA or a combination of multiple RNAs.

[0096] Example 1 Screening of Exosomal miRNA Biomarkers Associated with Early Lung Cancer Based on High-Throughput Sequencing

[0097] To screen for exosomal biomarkers related to the diagnosis of early lung cancer, 72 patients with early lung cancer diagnosis and 50 controls were recruited. Blood samples of no less than 10 ml were taken and plasma was separated. Exosomes in the plasma were isolated using the classical ultracentrifugation method, and RNA was extracted using the qiagen miRNeasy mini kit. The obtained RNA was used for small RNA library construction and sequencing. Bioinformatics analysis was performed on the obtained data to compare the differentially expressed miRNAs in patients with early lung cancer and controls, and the significantly differentially expressed miRNAs are shown in Table 2 below. These RNA-level biomarkers from exosomes can be used for the early diagnosis of lung cancer.

[0098] Table 2

[0099]

[0100]

[0101]

[0102] Example 2 miRNA Detection System Based on the Fluorescent Quantitative PCR Platform

[0103] 1. miRNA Reverse Transcription Reaction System

[0104] The miRNA reverse transcription reagents, enzymes, and oligodT were purchased from TAKARA. The standard products were synthesized by Shanghai Invitrogen, and the specific reverse primers were synthesized by Suzhou Hinxton. A 20-μl reverse transcription system was used, as shown in Table 3 below.

[0105] Table 3

[0106]

[0107] 2. PCR Reaction System

[0108] The PCR reaction mixture was purchased from TAKARA. The upstream primers, probes, and universal downstream primers were synthesized by Suzhou Hinxton, and the fluorescent quantitative PCR instrument was the ABI 7500. The PCR reaction system is shown in Table 4 below.

[0109] Table 4

[0110]

[0111] The PCR program was 10 min at 95°C, 15 cycles of (15 s at 95°C; 30 s at 55°C) without fluorescence collection, and 35 cycles of (15 s at 95°C; 30 s at 55°C) with fluorescence collection.

[0112] Evaluation of the detection effect of early-stage lung cancer diagnosis using Cel-miR-39 as a reference single biomarker other than in Example 3

[0113] 1. Sample collection

[0114] Collect 10 ml of blood from patients with early-stage (stage I and II) pulmonary nodule lung cancer, patients with benign pulmonary nodules, and healthy controls who have been diagnosed by a hospital, and separate it into plasma.

[0115] 2. Extraction of exosomal RNA

[0116] Separate plasma exosomes by ultracentrifugation or using Exosupur from Echobiotech (Beijing Enzekangtai) (the results of exosome electron microscopy identification are as Figure 1 ), and extract miRNAs in the exosomes from the separated exosomes using the Qiagen miReasy mini kit, and detect the RNA concentration and quality using an Agilent 2100, and record the RNA concentration.

[0117] 3. Two-step RNA detection system

[0118] Use the two-step detection system for miRNAs based on the PCR platform in Example 1 to detect the plasma exosomal miRNAs of 30 early-stage lung cancer patients and 30 control samples (healthy people and benign nodules), detect the Ct values of the target miRNAs, and calculate the relative expression levels according to the Ct values and the relative quantification formula.

[0119] 4. Evaluation of the performance of exosomal miRNAs in diagnosing early-stage lung cancer

[0120] (1) Evaluation of the performance of miR-3615 alone

[0121] As Figure 2As shown, the Ct values of miR-3615 in the plasma exosomes of 30 early lung cancer patients and 30 control samples (healthy people and benign lesions) were detected. Using the external reference Cel-miR-39 as a reference, the copy number of miRNA was obtained according to the Ct value. The relative quantitative formula value was used to calculate the fold change of the relative expression level of the combined marker, and then the relative expression level of RNA was obtained. The t-test analysis of the test results using R language showed that pvalue = 0.00058 <= 0.05, indicating that exosomal miR-3615 was significantly correlated with early lung cancer. The AUC of miR-3615 for the diagnosis of early lung cancer alone was 0.785, with a negative predictive value of 85%, a sensitivity of 90%, and a specificity of 56.57%, showing the potential of a diagnostic marker.

[0122] (2) Performance evaluation of miR-502-3p detection alone

[0123] As Figure 3 shown, the Ct values of miR-502-3p in the plasma exosomes of 30 early lung cancer patients and 30 control samples (healthy people and benign lesions) were detected. Using the external reference Cel-miR-39 as a reference, the copy number of miRNA was obtained according to the Ct value. The relative quantitative formula value was used to calculate the fold change of the relative expression level of the combined marker, and then the relative expression level of RNA was obtained. The t-test analysis of the test results using R language showed that pvalue = 0.00139 <= 0.05, indicating that exosomal miR-502-3p was significantly correlated with early lung cancer. The AUC of miR-502-3p for the diagnosis of early lung cancer alone was 0.756, with a negative predictive value of 68.42%, a sensitivity of 60%, and a specificity of 86.67%, showing the potential of a diagnostic marker.

[0124] (3) Performance evaluation of miR-450b-5p detection alone

[0125] As Figure 4 shown, the Ct values of miR-450b-5p in the plasma exosomes of 30 early lung cancer patients and 30 control samples (healthy people and benign lesions) were detected. Using the external reference Cel-miR-39 as a reference, the copy number of miRNA was obtained according to the Ct value. The relative quantitative formula value was used to calculate the fold change of the relative expression level of the combined marker, and then the relative expression level of RNA was obtained. The t-test analysis of the test results using R language showed that pvalue = 0.00199 <= 0.05, indicating that exosomal miR-450b-5p was significantly correlated with early lung cancer. The AUC of miR-450b-5p for the diagnosis of early lung cancer alone was 0.744, with a negative predictive value of 80%, a sensitivity of 86.67%, and a specificity of 53.33%, showing the potential of a diagnostic marker.

[0126] (4) Performance evaluation of miR-4746-5p alone

[0127] As Figure 5 shown, the Ct values of miR-4746-5p were detected in the plasma exosomes of 30 early lung cancer patients and 30 control samples (healthy people and benign lesions). Using the external reference Cel-miR-39 as a reference, the copy number of miRNA was obtained according to the Ct value. Using the relative quantitative formula value, the fold change of the relative expression level of the combined marker was calculated, and then the relative expression level of RNA was obtained. The t-test analysis was performed on the test results using R language, and the pvalue = 0.00183 <= 0.05, indicating that exosomal miR-4746-5p was significantly correlated with early lung cancer. The AUC of miR-4746-5p for the diagnosis of early lung cancer alone was 0.743, its negative predictive value was 66.67%, the sensitivity was 60%, and the specificity was 80%, showing the potential of a diagnostic marker.

[0128] (5) Performance evaluation of miR-10a-5p alone

[0129] As Figure 6 shown, the Ct values of miR-10a-5p were detected in the plasma exosomes of 30 early lung cancer patients and 30 control samples (healthy people and benign lesions). Using the external reference Cel-miR-39 as a reference, the copy number of miRNA was obtained according to the Ct value. Using the relative quantitative formula value, the fold change of the relative expression level of the combined marker was calculated, and then the relative expression level of RNA was obtained. The t-test analysis was performed on the test results using R language, and the pvalue = 0.00183 <= 0.05, indicating that exosomal miR-10a-5p was significantly correlated with early lung cancer. The AUC of miR-10a-5p for the diagnosis of early lung cancer alone was 0.73, its negative predictive value was 77.27%, the sensitivity was 83.33%, and the specificity was 56.67%, showing the potential of a diagnostic marker.

[0130] (6) Performance evaluation of other markers significantly correlated with early lung cancer

[0131] The performance evaluation of other significantly correlated miRNAs is shown in Table 5 below.

[0132] Table 5

[0133]

[0134]

[0135] It can be seen from the data shown in Table 5 that the miRNAs described in the table all have the potential of diagnostic markers.

[0136] Evaluation of the Detection Effect of a Multi-Marker Combination for Early Diagnosis of Lung Cancer with Cel-miR-39 as a Reference Except for Example 4

[0137] 1. Performance Evaluation of the Three-Marker Combination

[0138] Calculate the relative expression level of each miRNA according to the method in Example 3, and use logistic regression to train the three-marker combination. The combinations with an AUC of more than 0.85 for the three-marker combination are shown in Table 6 below. Among them, the two combinations of miR-106-3p + miR-125a-5p + miR-3615 and miR-106b-3p + miR-3615 + miR-450b-5p have the best performance, with AUC values of 0.887 and 0.881 respectively. Their AUC curves are shown in Figure 7 and Figure 8 respectively.

[0139] Table 6

[0140]

[0141]

[0142] 2. Performance Evaluation of the Five-Marker Combination

[0143] Calculate the relative expression level of each miRNA according to the method in Example 3, and use logistic regression to train the five-marker combination. The combinations with an AUC of more than 0.93 for the five-marker combination are shown in Table 7 below. Among them, the two combinations of miR-106b-3p + miR-125a-5p + miR-3615 + miR-450b-5p + miR-885-5p and miR-106b-3p + miR-10a-3p + miR-125a-5p + miR-3615 + miR-450b-5p have the best performance, with AUC values of 0.951 and 0.948 respectively. Their AUC curves are shown in Figure 9 and Figure 10 respectively.

[0144] Table 7

[0145]

[0146]

[0147] Evaluation of the Detection Effect of a Multi-Marker Combination for Early Diagnosis of Lung Cancer with U6 as a Reference within Example 5

[0148] Calculate the relative expression levels of each miRNA with U6 as the reference according to the method in Example 3. Use logistic regression to train the five biomarker combinations. The combinations with an AUC of more than 85 for the five-biomarker combinations are shown in Table 8 below. Among them, the combination of mmiR-106b-3P + miR-10a-5p + miR-125a-5p + miR-3615 + miR-450b-5p has the best performance, with an AUC of 0.864. Its AUC curve is respectively as Figure 11 shown.

[0149] Table 8

[0150]

[0151]

[0152] It can be seen from the above data that the lung cancer detection method based on exosomal miRNA markers of the present invention can achieve non-invasive diagnosis of lung cancer, provides important value for the early diagnosis and recurrence monitoring of lung cancer, and is very helpful for the prevention and treatment of lung cancer in China. Among them, the 5 miRNA biomarkers (the combined AUC can reach up to 0.951, with a negative predictive value of 90.32%, a sensitivity of 90.00%, and a specificity of 93.33%) have extremely excellent diagnostic performance.

[0153] The preferred embodiments of the present invention disclosed above are only used to help explain the present invention. The preferred embodiments do not describe all the details in detail, nor limit the invention to the specific embodiments described. Obviously, many modifications and variations can be made according to the content of this specification. These embodiments are selected and specifically described in this specification to better explain the principle and practical application of the present invention, so that those skilled in the art can well understand and utilize the present invention. The present invention is only limited by the claims and their full scope and equivalents. Sequence Listing <110> Cancer Hospital, Chinese Academy of Medical Sciences <120> Application of Exosomal miR-106b-3p, miR-450b-5p, etc. in the Diagnosis of Lung Cancer <130> 200001 <160> 80 <170> SIPOSequenceListing 1.0 <210> 1 <211> 50 <212> DNA <213> Artificial Sequence <400> 1 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgaaaga 50 <210> 2 <211> 21 <212> DNA <213> Artificial Sequence <400> 2 cgcgccctat acaatctact g 21 <210> 3 <211> 24 <212> DNA <213> Artificial Sequence <400> 3 tcgcactgga tacgacgaaa gaca 24 <210> 4 <211> 50 <212> DNA <213> Artificial Sequence <400> 4 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacggaaag 50 <210> 5 <211> 21 <212> DNA <213> Artificial Sequence <400> 5 agcgcctata cagtctactg t 21 <210> 6 <211> 24 <212> DNA <213> Artificial Sequence <400> 6 tcgcactgga tacgacggaa agac 24 <210> 7 <211> 50 <212> DNA <213> Artificial Sequence <400> 7 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgcagca 50 <210> 8 <211> 17 <212> DNA <213> Artificial Sequence <400> 8 accgcactgt gggtact 17 <210> 9 <211> 22 <212> DNA <213> Artificial Sequence <400> 9 tcgcactgga tacgacgcag ca 22 <210> 10 <211> 50 <212> DNA <213> Artificial Sequence <400> 10 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactattcc 50 <210> 11 <211> 21 <212> DNA <213> Artificial Sequence <400> 11 acgcgcaaat tcgtatctag g 21 <210> 12 <211> 25 <212> DNA <213> Artificial Sequence <400> 12 ttcgcactgg atacgactat tcccc 25 <210> 13 <211> 50 <212> DNA <213> Artificial Sequence <400> 13 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccacaaa 50 <210> 14 <211> 20 <212> DNA <213> Artificial Sequence <400> 14 cgctaccctg tagatccgaa 20 <210> 15 <211> 25 <212> DNA <213> Artificial Sequence <400> 15 ttcgcactgg atacgaccac aaatt 25 <210> 16 <211> 50 <212> DNA <213> Artificial Sequence <400> 16 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactcacag 50 <210> 17 <211> 20 <212> DNA <213> Artificial Sequence <400> 17 cgtccctgag accctttaac 20 <210> 18 <211> 24 <212> DNA <213> Artificial Sequence <400> 18 tcgcactgga tacgactcac aggt 24 <210> 19 <211> 50 <212> DNA <213> Artificial Sequence <400> 19 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacagacaa 50 <210> 20 <211> 19 <212> DNA <213> Artificial Sequence <400> 20 tgctgtgagg ttggcattg 19 <210> 21 <211> 24 <212> DNA <213> Artificial Sequence <400> 21 ttcgcactgg atacgacaga caac 24 <210> 22 <211> 50 <212> DNA <213> Artificial Sequence <400> 22 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactcagtt 50 <210> 23 <211> 20 <212> DNA <213> Artificial Sequence <400> 23 cgctgtgcaa atctatgcaa 20 <210> 24 <211> 25 <212> DNA <213> Artificial Sequence <400> 24 tcgcactgga tacgactcag ttttg 25 <210> 25 <211> 50 <212> DNA <213> Artificial Sequence <400> 25 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacacagtt 50 <210> 26 <211> 19 <212> DNA <213> Artificial Sequence <400> 26 accaagctgc cagttgaag 19 <210> 27 <211> 24 <212> DNA <213> Artificial Sequence <400> 27 tcgcactgga tacgacacag ttct 24 <210> 28 <211> 50 <212> DNA <213> Artificial Sequence <400> 28 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactaaccg 50 <210> 29 <211> 20 <212> DNA <213> Artificial Sequence <400> 29 cccgtagcac catctgaaat 20 <210> 30 <211> 24 <212> DNA <213> Artificial Sequence <400> 30 ttcgcactgg atacgactaa ccga 24 <210> 31 <211> 50 <212> DNA <213> Artificial Sequence <400> 31 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccttcca 50 <210> 32 <211> 21 <212> DNA <213> Artificial Sequence <400> 32 accgctgtaa acatccttga c 21 <210> 33 <211> 22 <212> DNA <213> Artificial Sequence <400> 33 tcgcactgga tacgaccttc ca 22 <210> 34 <211> 50 <212> DNA <213> Artificial Sequence <400> 34 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgtcctg 50 <210> 35 <211> 19 <212> DNA <213> Artificial Sequence <400> 35 acgaagggct tcctctctg 19 <210> 36 <211> 22 <212> DNA <213> Artificial Sequence <400> 36 tcgcactgga tacgacgtcc tg 22 <210> 37 <211> 50 <212> DNA <213> Artificial Sequence <400> 37 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgcctaa 50 <210> 38 <211> 18 <212> DNA <213> Artificial Sequence <400> 38 actctctggg cctgtgtc 18 <210> 39 <211> 22 <212> DNA <213> Artificial Sequence <400> 39 tcgcactgga tacgacgcct aa 22 <210> 40 <211> 50 <212> DNA <213> Artificial Sequence <400> 40 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacctagag 50 <210> 41 <211> 19 <212> DNA <213> Artificial Sequence <400> 41 agcctccgtg ttacctgtc 19 <210> 42 <211> 24 <212> DNA <213> Artificial Sequence <400> 42 tcgcactgga tacgacctag agga 24 <210> 43 <211> 50 <212> DNA <213> Artificial Sequence <400> 43 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgagccg 50 <210> 44 <211> 17 <212> DNA <213> Artificial Sequence <400> 44 cctctctcgg ctcctcg 17 <210> 45 <211> 22 <212> DNA <213> Artificial Sequence <400> 45 tcgcactgga tacgacgagc cg 22 <210> 46 <211> 50 <212> DNA <213> Artificial Sequence <400> 46 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacccatct 50 <210> 47 <211> 18 <212> DNA <213> Artificial Sequence <400> 47 gcgactggac ttggtgtc 18 <210> 48 <211> 23 <212> DNA <213> Artificial Sequence <400> 48 tcgcactgga tacgacccat ctg 23 <210> 49 <211> 50 <212> DNA <213> Artificial Sequence <400> 49 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgggcgg 50 <210> 50 <211> 19 <212> DNA <213> Artificial Sequence <400> 50 agcatcggga atgtcgtgt 19 <210> 51 <211> 21 <212> DNA <213> Artificial Sequence <400> 51 tcgcactgga tacgacgggc g 21 <210> 52 <211> 50 <212> DNA <213> Artificial Sequence <400> 52 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactattca 50 <210> 53 <211> 21 <212> DNA <213> Artificial Sequence <400> 53 tccgcttttg caatatgttc c 21 <210> 54 <211> 26 <212> DNA <213> Artificial Sequence <400> 54 ttcgcactgg atacgactat tcagga 26 <210> 55 <211> 50 <212> DNA <213> Artificial Sequence <400> 55 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactctgca 50 <210> 56 <211> 17 <212> DNA <213> Artificial Sequence <400> 56 ccggtcccag gagaacc 17 <210> 57 <211> 22 <212> DNA <213> Artificial Sequence <400> 57 tcgcactgga tacgactctg ca 22 <210> 58 <211> 50 <212> DNA <213> Artificial Sequence <400> 58 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacaagacg 50 <210> 59 <211> 18 <212> DNA <213> Artificial Sequence <400> 59 cgctcactcc tctcctcc 18 <210> 60 <211> 23 <212> DNA <213> Artificial Sequence <400> 60 tcgcactgga tacgacaaga cgg 23 <210> 61 <211> 50 <212> DNA <213> Artificial Sequence <400> 61 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactgaatc 50 <210> 62 <211> 18 <212> DNA <213> Artificial Sequence <400> 62 acaatgcacc tgggcaag 18 <210> 63 <211> 25 <212> DNA <213> Artificial Sequence <400> 63 ttcgcactgg atacgactga atcct 25 <210> 64 <211> 50 <212> DNA <213> Artificial Sequence <400> 64 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacgggctc 50 <210> 65 <211> 19 <212> DNA <213> Artificial Sequence <400> 65 cgagtgcctg agggagtaa 19 <210> 66 <211> 22 <212> DNA <213> Artificial Sequence <400> 66 tcgcactgga tacgacgggc tc 22 <210> 67 <211> 50 <212> DNA <213> Artificial Sequence <400> 67 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccaaaag 50 <210> 68 <211> 21 <212> DNA <213> Artificial Sequence <400> 68 cgcgctttag gataagcttg a 21 <210> 69 <211> 25 <212> DNA <213> Artificial Sequence <400> 69 ttcgcactgg atacgaccaa aagtc 25 <210> 70 <211> 50 <212> DNA <213> Artificial Sequence <400> 70 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactctcgg 50 <210> 71 <211> 17 <212> DNA <213> Artificial Sequence <400> 71 tgaagcgcct gtgctct 17 <210> 72 <211> 23 <212> DNA <213> Artificial Sequence <400> 72 tcgcactgga tacgactctc ggc 23 <210> 73 <211> 50 <212> DNA <213> Artificial Sequence <400> 73 gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgacagaggc 50 <210> 74 <211> 20 <212> DNA <213> Artificial Sequence <400> 74 acgctccatt acactaccct 20 <210> 75 <211> 22 <212> DNA <213> Artificial Sequence <400> 75 tcgcactgga tacgacagag gc 22 <210> 76 <211> 17 <212> DNA <213> Artificial Sequence <400> 76 ctcgcttcgg cagcaca 17 <210> 77 <211> 20 <212> DNA <213> Artificial Sequence <400> 77 aacgcttcac gaatttgcgt 20 <210> 78 <211> 20 <212> DNA <213> Artificial Sequence <400> 78 aacgcttcac gaatttgcgt 20 <210> 79 <211> 25 <212> DNA <213> Artificial Sequence <400> 79 agaagattag catggcccct gcgca 25 <210> 80 <211> 16 <212> DNA <213> Artificial Sequence <400> 80 gtgcagggtc cgaggt 16

Claims

1. Use of a primer and a probe for detecting miRNA markers in plasma exosomes in the preparation of a lung cancer diagnostic kit, characterized in that, The exosomal miRNA markers are a combination of miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-3615, and miR-450b-5p.

2. The application according to claim 1, wherein The primers and probes include: Reverse transcription primer, PCR primers, and probe for detecting miR-106b-3p: The reverse transcription primer of miR-106b-3p has the nucleotide sequence shown in SEQ ID NO: 7, the PCR upstream primer has the nucleotide sequence shown in SEQ ID NO: 8, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 9; Reverse transcription primer, PCR primers, and probe for detecting miR-10a-5p: The reverse transcription primer of miR-10a-5p has the nucleotide sequence shown in SEQ ID NO: 13, the PCR upstream primer has the nucleotide sequence shown in SEQ ID NO: 14, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 15; Reverse transcription primer, PCR primers, and probe for detecting miR-125a-5p: The reverse transcription primer of miR-125a-5p has the nucleotide sequence shown in SEQ ID NO: 16, the PCR upstream primer has the nucleotide sequence shown in SEQ ID NO: 17, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 18; Reverse transcription primer, PCR primers, and probe for detecting miR-3615: The reverse transcription primer of miR-3615 has the nucleotide sequence shown in SEQ ID NO: 43, the PCR upstream primer has the nucleotide sequence shown in SEQ ID NO: 44, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO: 45; Reverse transcription primer, PCR primers, and probe for detecting miR-450b-5p: The reverse transcription primer of miR-450b-5p has the nucleotide sequence shown in SEQ ID NO: 52, the PCR upstream primer has the nucleotide sequence shown in SEQ ID NO: 53, the downstream primer has the nucleotide sequence shown in SEQ ID NO: 80, and the probe has the nucleotide sequence shown in SEQ ID NO:

54.

3. Use of a primer and a probe for detecting miRNA markers in plasma exosomes in the preparation of a device for diagnosing lung cancer, characterized in that, The exosomal miRNA markers are a combination of miR-106b-3p, miR-10a-5p, miR-125a-5p, miR-3615, and miR-450b-5p.

Images